Proquad Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The proquad market research report is one of a series of new reports that provides proquad market statistics, including proquad industry global market size, regional shares, competitors with a proquad market share, detailed proquad market segments, market trends and opportunities, and any further data you may need to thrive in the proquad industry. This proquad market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to population growth, improved access to healthcare, global health initiatives, rising awareness of vaccine-preventable diseases, government vaccination funding, and a growing focus on preventive healthcare. Major trends in the forecast period include global vaccination coverage, technological advancements in vaccine delivery, integration of vaccines in routine health systems, improvements in vaccine accessibility, and increased awareness of vaccine safety.

The growing number of measles and chickenpox cases is expected to drive the expansion of the proquad market. Measles is a highly contagious viral disease that causes fever, cough, and a red rash, and is preventable through vaccination. Similarly, chickenpox, caused by the Varicella-zoster virus, results in an itchy blister-like rash and can be prevented with a vaccine. The rise in these diseases is primarily due to declining vaccination rates, misinformation about vaccines, increased international travel, and outbreaks among unvaccinated populations, which have contributed to the resurgence of these preventable illnesses. Proquad, a combination vaccine for measles, mumps, rubella, and varicella (chickenpox), offers protection through a single dose, reducing infection risks, controlling outbreaks, and ensuring comprehensive coverage to prevent complications from these diseases. According to the World Health Organization, 56,634 measles cases and four deaths were reported in the first quarter of 2024 across 45 countries in the European region, highlighting the increasing incidence and driving the demand for vaccines such as Proquad.

The increasing healthcare expenditures are also expected to fuel the growth of the proquad market. Healthcare expenditures refer to the total amount spent on healthcare services, products, and activities within a given period, whether on an individual, community, national, or global scale. The rise in these expenditures is driven by factors such as the growing prevalence of chronic diseases, an aging population, advancements in medical technology, and the increasing demand for more sophisticated treatments and healthcare services. These expenditures help fund immunization programs, improve accessibility, boost public awareness, and ensure that the necessary infrastructure and insurance coverage are in place to support the widespread use of vaccines such as Proquad. For example, in 2023, healthcare spending in the UK totaled approximately $362 billion, reflecting a 5.6% increase from the previous year, underscoring the growing financial commitment to healthcare and its impact on vaccine distribution.

A significant trend in the proquad market is the shift toward expanding vaccine administration options, such as intramuscular (IM) administration, to improve efficiency and consistency in immunization practices. IM administration involves delivering a vaccine or medication directly into the muscle, which allows for quicker absorption into the bloodstream. In March 2023, Merck & Co. Inc. received approval from the U.S. Food and Drug Administration (FDA) to add an intramuscular administration option to the product label for its MMRV vaccine family, which includes ProQuad. With this approval, healthcare professionals now have the option to administer vaccines such as ProQuad via the same intramuscular route used for other routinely recommended injectable pediatric vaccines. This expansion in administration options enhances the convenience of immunizations and aligns with broader efforts to streamline vaccine delivery.

The key company operating in the proquad market is Merck and Co. Inc.

North America was the largest region in the proquad market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in proquad report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the proquad market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Proquad is a combination vaccine designed to protect against measles, mumps, rubella (MMR), and varicella (chickenpox). By combining multiple vaccines into one shot, it reduces the number of injections needed for immunization. It is primarily administered to children, typically as a single dose for those aged 12 months to 12 years.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main indications for Proquad include protection against measles, mumps, rubella, and varicella. The measles segment focuses on vaccines aimed at preventing measles, a highly contagious viral disease, which is administered during childhood as part of the MMR combination vaccine. The patient population for Proquad includes both pediatric and adult patients, with distribution through healthcare providers, pharmacies, and public health organizations.

The proquad market consists of sales of proquad lyophilized suspension for injection, subcutaneous injection and intramuscular injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.